LAW
Ovid Halts Preclinical Work and IV Seizure Program Following Soticlestat’s Phase 3 Setbacks
Ovid Therapeutics, soticlestat, Phase 3 trials, Dravet syndrome, Lennox-Gastaut syndrome, preclinical work, IV seizure program, Takeda Pharmaceutical
Agios’ Pyrukynd Misses Primary Endpoint in First Pediatric Study for Rare Blood Disorder
Agios Pharmaceuticals, Pyrukynd, mitapivat, PK deficiency, pediatric study, blood disorder, Phase 3 ACTIVATE-KidsT study
Healx Initiates Phase II Trial for AI-Discovered Rare Disease Candidate with $47M Funding
Healx, AI-discovered, rare disease, neurofibromatosis Type 1, Phase II trial, $47M funding
Ventyx Abandons TYK2 Inhibitor Development Following Phase II Failure in Crohn’s Disease
Ventyx Biosciences, TYK2 inhibitor, VTX958, Crohn’s disease, Phase II trial, drug development failure
Cognition Therapeutics’ Stock Plummets Following Disappointing Phase 2 Alzheimer’s Trial Results
Cognition Therapeutics, Alzheimer’s disease, Phase 2 trial, stock decline, CT1812, oral treatment, efficacy endpoint
Bristol Myers Squibb Resumes Radiopharmaceutical Phase 3 Trial Following Isotope Shortage
Bristol Myers Squibb, Radiopharmaceutical, Phase 3 Trial, Isotope Shortage, RYZ101, Actinium-225
Viking Therapeutics Accelerates Obesity Drug Development to Phase 3 Trials
Viking Therapeutics, Obesity Drug, Phase 3 Trials, GLP-1/GIP Receptor Agonist, VK2735, Weight Loss, Market Competition
Ionis Advances to Phase 3 Trial for Angelman Syndrome Treatment ION582
Ionis Pharmaceuticals, Angelman syndrome, ION582, Phase 3 trial, antisense oligonucleotides, neurological conditions, rare diseases, Biogen, Ultragenyx Pharmaceutical
G1 Therapeutics to Lay Off Staff After Cosela Fails in Pivotal Breast Cancer Study
G1 Therapeutics, Cosela, Breast Cancer, Layoffs, Phase 3 Trial, Trilaciclib, Metastatic Triple Negative Breast Cancer
PTC Therapeutics Reports Positive Phase II Huntington’s Disease Data, FDA Lifts Partial Clinical Hold
PTC Therapeutics, Huntington’s disease, Phase II data, FDA, partial clinical hold, PTC518, mutant huntingtin protein, clinical trends, safety, tolerability.